News

Showing ##res## items
Active Filters:
  • Experts say participation by people of color in clinical cancer trials is low because of distrust, access, and other factors. Less than 10 percent of people with cancer in the United States participate in clinical trials. Here are some reasons why. When Susan Gubar received a diagnosis of ovarian cancer for the third...
  • Cancer kills more people in the United States than accidents, stroke, Alzheimer’s and diabetes combined. In 2017, despite spending 147 billion U.S. healthcare dollars on cancer care, 600,000 people died from cancer and 1.7 million new people were diagnosed with cancer. But the news is not all grim: in all, 2.6 million...
  • (HealthDay News) -- Before a new cancer treatment is available to the public, it must undergo vigorous evaluation, the American Cancer Society says. Typically, a new treatment is tested on cancer cells in a laboratory. If testing is deemed successful, there may be testing on animals, followed by testing on people....
  • You've marched in the Women's March, cheered for women in Congress, grappled with the wide-ranging implications of the MeToo movement, talked with your kids (of both genders) about sexual harassment. Wait -- did you forget to sign up for a medical study? In the new pantheon of Women's Causes We Care About, inclusion...
  • (Reuters Health) - Patients, their families and friends may see clinical trial research as important, yet they don't know much about the research process and see trial participation as burdensome, a new study suggests. About 85 percent of respondents in the new study said clinical research is important to developing...
  • When Ann Graham was diagnosed at age 43 with osteosarcoma, a rare bone cancer that typically occurs in children and young adults, all she really heard was “cancer,” not the “rare” part. But Graham, a nonprofit executive, married mother of three, and grandmother of one from Vermont, soon learned that while every cancer...
  • (Reuters Health) - When terminally ill Americans receive experimental medicines through so-called "compassionate use" programs, they typically only get these drugs after extensive tests for safety and effectiveness, a U.S. study suggests. "This means that sufficient evidence of safety and effectiveness has been...
  • NEW YORK (Reuters Health) - Women with HER2-positive early-stage breast cancer do just as well if they take adjuvant trastuzumab for six months rather than the current standard 12 months, according to a large phase 3 study. "Everyone involved in this study is very excited by these results," Dr. Helena Earl, professor...
  • (Reuters) - Merck & Co said on Wednesday its drug Keytruda helped patients with metastatic squamous non-small cell lung cancer (sNSCLC) live longer and prevented the disease from spreading, helping to solidify its position in the lucrative cancer market. Keytruda, already approved for other types of cancer, is...
  • A promising new field of cancer treatment called cancer immunotherapy has been exploding — and with it, hundreds of trials that aim to get to a better understanding of which combinations of treatments work and which don't. Dr. Norman Sharpless, the director of the National Cancer Institute, said that the agency has a...
  • If you have prostate cancer, you likely know there are certain treatments doctors use for most patients. But researchers are working toward more personalized therapies. Typically, if you have localized cancer, doctors may choose to monitor the cancer’s status, but defer treatment for a time, or treat with surgery or...
  • By Reuters Staff (Reuters) - U.S. regulators have approved expanded use of Eli Lilly and Co's Verzenio breast cancer drug as an initial treatment for certain women with advanced or metastatic disease, a decision that should boost sales of the medicine, the company said on Monday. The Food and Drug Administration...
  • NEW YORK (Reuters Health) - Pooled data from studies of second-line therapy for non-small cell lung cancer (NSCLC) indicate that compared to docetaxel, checkpoint inhibitors are associated with better survival in some patients but not others. Dr. Chee Khoon Lee told Reuters Health by email, "The finding of no overall...
  • NEW YORK (Reuters Health) - The CDK4/6 inhibitor ribociclib added to standard endocrine therapy with ovarian suppression significantly improves progression-free survival (PFS) in pre- and perimenopausal women with advanced hormone-receptor (HR)-positive, HER2-negative breast cancer, according to results of the...
  • FRIDAY, Jan. 12, 2018 (HealthDay News) -- Survival appears to be similar for patients with young-onset breast cancer who carry a BRCA mutation and noncarriers, according to a study published online Jan. 11 in The Lancet Oncology. Ellen R. Copson, Ph.D., from the University of Southampton in the United Kingdom, and...
  • ZURICH (Reuters) - Novartis's Kisqali (ribociclib) has won U.S. Food and Drug Administration breakthrough therapy designation for treating some breast cancer patients, the Swiss drugmaker said on Wednesday. The designation covers initial endocrine-based treatment of pre- or perimenopausal women with hormone-receptor...
  • ZURICH (Reuters) - Adding Roche's immunotherapy Tecentriq to older drugs doubled the percentage of lung cancer patients who survived a year without their disease advancing, an outcome some experts labeled unprecedented. Thirty-seven percent of patients in a closely watched clinical trial who received Tecentriq,...
  • WEDNESDAY, Dec. 6, 2017 (HealthDay News) -- Adding a new drug to standard treatment can slow the progression of advanced breast cancer in younger women, a new clinical trial has found. The drug, called ribociclib (Kisqali), was approved by the U.S. Food and Drug Administration in March for the treatment of...
  • By Reuters Staff NEW YORK (Reuters Health) - In women with early breast cancer, neoadjuvant chemotherapy (NACT) results in higher rates of breast-conserving therapy than adjuvant chemotherapy, without compromising on distant recurrence, breast cancer survival, or overall survival, but with higher rates of local...
  • * Win tilts competitive landscape in big lung cancer market * Roche, Merck & Co main backers of chemo-combo therapy * AstraZeneca, Bristol-Myers betting on dual immunotherapies LONDON, Nov 20 (Reuters) - Cancer doctors struggling to work out the best way to use modern immunotherapy drugs now have further evidence...